Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference summary

Company overview and recent performance

• Two commercial products in hematology: one for acute AML, another for chronic GVHD, with three approvals in about a year.

• Achieved record first-year sales for AML product, with $44M in Q4 and $125M for the full year, and high formulary coverage.

• Organization is well-scaled and financially positioned to reach profitability in the near term, with cash reserves to support operations.

Product launches and growth drivers

• Revuforj's launch driven by KMT2A and NPM1 indications, with about 50% market penetration in KMT2A and growing NPM1 share post-approval.

• Post-transplant maintenance is a significant growth driver, with 40%-45% of transplant patients returning to therapy.

• Duration of therapy expected to increase from 4-6 months in year one to 6-12 months in year two, supporting revenue growth.

Market opportunity and financial outlook

• Total addressable market for relapsed/refractory AML estimated at over $2B, with $750M for KMT2A and $1.2B-$1.4B for NPM1.

• Frontline opportunity could reach $10B for both products combined, with longer therapy durations.

• Niktimvo in chronic GVHD has a third-line+ market of 6,500 patients and a potential $2B+ opportunity, expanding to $5B+ in frontline.